City Therapeutics (CTY) Stock: Why It Fell
Updated Oct 20, 2026, 4:00 PM ET · closing price
- Latest session (Tue Oct 20): $20.83, −$0.63 (-2.94%), volume 0.7x its 50-day average.
- Latest SEC filing: 4 on Oct 19, 2026 — insider trade report.
Sector peers moving today (Pharma & Biotech):MYGN +31.59%EVAX +21.62%IRLA +16.89%QNCX +16.89%LRMR +15.09%
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Pfizer (PFE)
CTY dips 2.9% to $20.83. Closed at $20.83, -2.94% vs the prior close of $21.46. Day range $20.01–$21.50, opened at $21.44.
Why Did CTY Stock Move Today?
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 20, 2026 — CTY dips 2.9% to $20.83
- Closed at $20.83, -2.94% vs the prior close of $21.46. Day range $20.01–$21.50, opened at $21.44.
- Volume was 632.53K shares, 0.7x its 50-day average of 854.25K.
- 52-week range $20.01–$23.88; today's close sits at 21% of that range, 12.8% below the 52-week high.
Oct 19, 2026 — CTY slides 4.2% to $21.46
- Closed at $21.46, -4.20% vs the prior close of $22.40. Day range $21.03–$22.00, opened at $21.94.
- Volume was 302.40K shares, 0.2x its 50-day average of 1.41M — lighter than usual.
- 52-week range $20.50–$23.88; today's close sits at 28% of that range, 10.1% below the 52-week high.
- SEC filings that day: 8-K.
CTY bull case vs bear case (from the data)
- No clear positive signal in the price trend, filings or insider data right now.
- High volatility: average daily move of 3.6% over 20 sessions.
Latest CTY SEC 8-K & 10-Q Filings
Every SEC filing by or about CTY in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Arch Venture Partners Xii, Llc & Arch Venture Partners Xii, L.P. & Arch Venture Fund Xii, L.P. & Crandell Keith & Burow Kristina & Gillis Steven converted 3,294,900 shares on Oct 19, 2026; now holds 6,013,192
- Arch Venture Partners Xii, Llc & Arch Venture Partners Xii, L.P. & Arch Venture Fund Xii, L.P. & Crandell Keith & Burow Kristina & Gillis Steven converted 5,482,309 shares on Oct 19, 2026; now holds 11,495,501
- Arch Venture Partners Xii, Llc & Arch Venture Partners Xii, L.P. & Arch Venture Fund Xii, L.P. & Crandell Keith & Burow Kristina & Gillis Steven converted 2,027,006 shares on Oct 19, 2026; now holds 13,522,507
- Arch Venture Partners Xii, Llc & Arch Venture Partners Xii, L.P. & Arch Venture Fund Xii, L.P. & Crandell Keith & Burow Kristina & Gillis Steven bought 170,000 shares at $18.00 (≈$3.06M) on Oct 19, 2026; now holds 13,692,507
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Nelsen Robert converted 3,294,900 shares on Oct 19, 2026; now holds 6,013,192
- Nelsen Robert converted 5,482,309 shares on Oct 19, 2026; now holds 11,495,501
- Nelsen Robert converted 2,027,006 shares on Oct 19, 2026; now holds 13,522,507
- Nelsen Robert bought 170,000 shares at $18.00 (≈$3.06M) on Oct 19, 2026; now holds 13,692,507
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Maraganore John converted 610,759 shares on Oct 19, 2026; now holds 1,470,692
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 19, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
Oct 16, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Oct 16, 2026 · Form 424B4 — Final prospectus with offering price
Final prospectus with offering price
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 15, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Oct 15, 2026 · Form S-1MEF — S-1MEF filing
S-1MEF filing
Oct 13, 2026 · Form 8-A12B — 8-A12B filing
8-A12B filing
Oct 9, 2026 · Form S-1/A — S-1/A filing
S-1/A filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 24, 2026 · Form S-1 — Registration statement (S-1)
Registration statement (S-1) — registering new shares, usually for an IPO or offering
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade CTY
- How much it moves: over the last 20 sessions the average daily move was 3.57% (largest 4.2%). That is a volatile stock.
- Liquidity: about 780.43K shares (≈$16.26M) trade per day on average.
- 52-week position: $20.83 vs a range of $20.00–$23.88 (21% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Oct 19, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
CTY market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 20, 2026 | 21.44 | 21.50 | 20.00 | 20.83 | 632.80K |
| Oct 19, 2026 | 21.94 | 22.00 | 21.03 | 21.46 | 302.40K |
| Oct 16, 2026 | 23.00 | 23.88 | 20.50 | 22.40 | 1.41M |
About City Therapeutics
City Therapeutics (CTY) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 2143850.
CTY board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| No Form 3/4/5 filings by this group in the last 12 months. | ||
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| No Form 3/4/5 filings by this group in the last 12 months. | ||
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
CTY financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
CTY earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)United Therapeutics (UTHR)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Space Exploration Technologies (SPCX)Tesla (TSLA)Sandisk (SNDK)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on CTY
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 20, 2026, 4:00 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.